{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.13","upperLimit":"80.81","value":"69.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants with complete and partial response as the best overall response, as determined by an IRC using PET-CT assessment data for participants with fluorodeoxyglucose (FDG)-avid disease","dispersionType":"95% Confidence Interval","groups":[{"description":"Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent","id":"OG000","title":"Zanubrutinib"}],"paramType":"NUMBER","populationDescription":"Efficacy analysis set consisted of evaluable participants with FDG-avid disease at baseline","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years and 2.5 months","title":"ORR by IRC Assessment Using Positron Emission Tomography-Computed Tomography (PET-CT)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}